P-327. Geospatial and temporal trends in HIV pre-exposure prophylaxis use across metropolitan counties of the United States from 2016 through 2022
Ronit Gupta, Johnny Yue, Ribhav Gupta

TL;DR
This study examines how access to HIV prevention medication, PrEP, has changed over time and across U.S. metropolitan counties from 2016 to 2022, highlighting regional disparities and the impact of a national initiative.
Contribution
The study provides a detailed geospatial and temporal analysis of PrEP use and access disparities across U.S. metropolitan counties, evaluating the impact of the Ending the HIV Epidemic initiative.
Findings
PrEP use rates and PrEP-to-need ratios increased significantly from 2016 to 2022, but disparities persisted across regions.
EHE counties showed measurable progress in PrEP access but still lagged behind non-EHE counties in terms of PrEP-to-need ratios.
Geospatial analysis identified hotspots and coldspots of PrEP access, with emerging hotspots in the Northwest and Southeast.
Abstract
HIV Pre-exposure prophylaxis (PrEP) remains a highly effective tool in HIV prevention. While studies on national gains in PrEP access, little is known about how access has over time and geography sub-nationally. We characterize trends in PrEP access across U.S. metropolitan counties from 2016-2022, identifies regional disparities, and evaluate the Ending the HIV Epidemic (EHE) initiative.Figure 1.County-level trends in metropolitan PrEP use rate (per 100,000 people) and PrEP-to-need ratio from 2016 through 2022.Panel A. PrEP use rate (per 100,000 people) on linear scale; Panel B. PrEP-to-need ratio on linear scale. Panel C. PrEP use rate (per 100,000 people) on log scale. Note: Variation in y-axis scale by panel.Figure 2.Geospatial trends in county-level PrEP-to-need ratio and PrEP use rates (per 100,000 people) across the metropolitan United States.Panel A. PrEP use rate (per 100,000…
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHIV/AIDS Research and Interventions · Data-Driven Disease Surveillance · HIV, Drug Use, Sexual Risk
